Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
Age
Any age
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthcare professionals working only in Saudi Arabia AND
Prescribers of Depakine® (sodium valiporate) at least once in the six months leading up to survey completion OR
Obstetricians/Gynecologists who consulted at least one women of childbearing potential treated with Depakine® (sodium valproate) in the six months leading up to survey completion OR
Pharmacists who have dispensed Depakine® (sodium valproate) in the six months leading up to survey completion
You may not be if
Healthcare professionals who may have conflicts of interest with the survey (i.e. employed by regulatory bodies or pharmaceutical companies)
Healthcare professionals (or with a relative) involved in valproate-related lawsuits or associations for victims of valproate syndrome
Healthcare professionals who are not prescribing Depakine® (sodium valproate), except for obstetricians/gynecologists (who do not prescribe Depakine® \[sodium valproate\])
Healthcare professionals having started to prescribe or dispense Depakine® (sodium valproate) earlier than six months before survey completion
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Clareo Health | A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia
